Does TISOTUMAB VEDOTIN Cause Malignant neoplasm progression? 8 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 8 reports of Malignant neoplasm progression have been filed in association with TISOTUMAB VEDOTIN (TIVDAK). This represents 4.8% of all adverse event reports for TISOTUMAB VEDOTIN.
8
Reports of Malignant neoplasm progression with TISOTUMAB VEDOTIN
4.8%
of all TISOTUMAB VEDOTIN reports
3
Deaths
3
Hospitalizations
How Dangerous Is Malignant neoplasm progression From TISOTUMAB VEDOTIN?
Of the 8 reports, 3 (37.5%) resulted in death, 3 (37.5%) required hospitalization.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for TISOTUMAB VEDOTIN. However, 8 reports have been filed with the FAERS database.
What Other Side Effects Does TISOTUMAB VEDOTIN Cause?
Anaemia (12)
Diarrhoea (12)
Febrile neutropenia (12)
Dry eye (10)
Neuropathy peripheral (9)
Conjunctivitis (8)
Dehydration (8)
Nausea (8)
Pyrexia (8)
Constipation (7)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which TISOTUMAB VEDOTIN Alternatives Have Lower Malignant neoplasm progression Risk?
TISOTUMAB VEDOTIN vs TISOTUMAB VEDOTIN-TFTV
TISOTUMAB VEDOTIN vs TITANIUM DIOXIDE\ZINC
TISOTUMAB VEDOTIN vs TIVICAY
TISOTUMAB VEDOTIN vs TIVOZANIB
TISOTUMAB VEDOTIN vs TIXOCORTOL PIVALATE